We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+43.89%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$2.32B
AUM Growth
+$601M
Cap. Flow
+$106M
Cap. Flow %
4.57%
Top 10 Hldgs %
72.02%
Holding
31
New
6
Increased
4
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$55.6M
2
DTIL icon
Precision BioSciences
DTIL
+$32.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$30.6M
4
IFRX icon
InflaRx
IFRX
+$27M
5
ALEC icon
Alector
ALEC
+$18.9M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$43.1M
2
ARVN icon
Arvinas
ARVN
+$17.7M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.1M
4
ASND icon
Ascendis Pharma A/S
ASND
+$9.47M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$486M 20.97%
4,132,442
-108,094
-3% -$9.47M
WVE icon
2
Wave Life Sciences
WVE
$1.12B
$302M 13.03%
7,775,207
+263,158
+4% +$10.7M
THOR
3
DELISTED
Synthorx, Inc. Common Stock
THOR
$198M 8.54%
9,724,598
– –
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$131M 5.65%
2,382,168
– –
RARX
5
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$109M 4.69%
4,858,260
– –
IFRX icon
6
InflaRx
IFRX
$243M
$106M 4.58%
2,810,708
+725,619
+35% +$27M
ORTX
7
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$91.3M 3.94%
510,833
+26,240
+5% +$3.94M
EIDX
8
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$91.1M 3.93%
2,162,671
– –
MYOV
9
DELISTED
Myovant Sciences Ltd.
MYOV
$84.6M 3.65%
3,544,227
-167,322
-5% -$3.42M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.42B
$70.5M 3.04%
8,659,983
-2,000,366
-19% -$17.1M
TGTX icon
11
TG Therapeutics
TGTX
$8.19B
$65.9M 2.84%
8,198,337
– –
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$61.1M 2.63%
+384,001
New +$55.6M
RYTM icon
13
Rhythm Pharmaceuticals
RYTM
$7.31B
$51.7M 2.23%
1,884,782
-65,550
-3% -$1.88M
AXSM icon
14
Axsome Therapeutics
AXSM
$11.7B
$46.9M 2.02%
+3,293,789
New +$30.6M
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$8.88B
$42.7M 1.84%
1,875,209
– –
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$41.2M 1.78%
1,441,070
– –
KALA icon
17
KALA BIO
KALA
$12.5M
$37.5M 1.62%
1,817
– –
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$37.3M 1.61%
2,563,657
+5,300
+0.2% +$67.7K
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$36M 1.55%
2,456,669
– –
EIGR
20
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$33.8M 1.46%
80,515
– –
DTIL icon
21
Precision BioSciences
DTIL
$178M
$33.1M 1.43%
+61,412
New +$32.6M
ARVN icon
22
Arvinas
ARVN
$530M
$31.6M 1.36%
2,138,412
-1,000,000
-32% -$17.7M
MRNA icon
23
Moderna
MRNA
$21.6B
$30.8M 1.33%
1,513,929
-397
-0% -$7.37K
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.04B
$24.8M 1.07%
2,610,510
-109,942
-4% -$1.07M
SLDB icon
25
Solid Biosciences
SLDB
$792M
$24.7M 1.07%
179,296
– –
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, RA Capital Management held 31 positions worth $2.32B, up 35% from $1.72B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

RA Capital Management deployed $106M of net new capital in Q1 2019, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Sage Therapeutics: 384,001 shares worth $61.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $17.7M trimmed.

  • RA Capital Management's largest Q1 2019 buy was Sage Therapeutics: 384,001 shares worth $61.1M.
  • RA Capital Management added most to InflaRx in Q1 2019, an estimated $27M increase.
  • RA Capital Management's biggest Q1 2019 reduction was Arvinas, cutting an estimated $17.7M.
  • RA Capital Management fully exited Immunomedics Inc in Q1 2019, selling an estimated $43.1M.
  • RA Capital Management's ten largest holdings make up 72% of its $2.32B portfolio in Q1 2019.
  • RA Capital Management opened 6 new positions and closed 2 in Q1 2019.
  • RA Capital Management's portfolio value rose 35% quarter-over-quarter to $2.32B.

Based on RA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.